MRKR FY2028 EPS Reduced by Brookline Capital Management

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Equities researchers at Brookline Capital Management dropped their FY2028 earnings per share estimates for shares of Marker Therapeutics in a research report issued to clients and investors on Thursday, May 15th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of $2.33 per share for the year, down from their prior estimate of $2.42. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Marker Therapeutics’ FY2029 earnings at $8.45 EPS.

Several other equities analysts have also issued reports on the company. WBB Securities reaffirmed a “strong-buy” rating and issued a $12.50 target price on shares of Marker Therapeutics in a report on Tuesday, April 1st. Canaccord Genuity Group initiated coverage on Marker Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $8.00 target price for the company.

Marker Therapeutics Stock Up 1.8%

MRKR stock opened at $1.13 on Monday. The firm has a market cap of $12.79 million, a PE ratio of -0.85 and a beta of 1.29. The business has a 50 day moving average of $1.17 and a 200-day moving average of $2.19. Marker Therapeutics has a 12-month low of $0.95 and a 12-month high of $5.99.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Wednesday, May 21st. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.26. The firm had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.50 million. Marker Therapeutics had a negative return on equity of 89.63% and a negative net margin of 179.74%.

Hedge Funds Weigh In On Marker Therapeutics

Institutional investors have recently bought and sold shares of the company. Millennium Management LLC purchased a new position in Marker Therapeutics in the fourth quarter valued at approximately $50,000. Northern Trust Corp lifted its stake in Marker Therapeutics by 66.9% in the fourth quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after purchasing an additional 21,703 shares during the last quarter. LPL Financial LLC purchased a new position in Marker Therapeutics in the fourth quarter valued at approximately $248,000. Aisling Capital Management LP lifted its stake in Marker Therapeutics by 3.5% in the fourth quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after purchasing an additional 11,084 shares during the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new position in Marker Therapeutics in the fourth quarter valued at approximately $1,724,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.